In line with this, the IL-6R inhibitor tocilizumab retarded DKD in a mouse model of obesity- and diabetes-induced DKD (db/db mice) mainly via suppressed activation of NLRP3-inflammasomes and blunted immune-mediated kidney damage (135). This evidence concerns the gene NLRP3 and diabetic kidney disease.